Evidence map›Paper›PMID 40550963›Full record

ArticleActa pharmacologica Sinica2025

Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma.

Yan-Ni Ma, Xu-Hui Ma, Mei-Ling Hao, Rui-Xin Liu, Yang Zheng, Jie Yang, Xiang-Yu Chen, Yi-Nan Chen, Sheng-Nan Zheng, Yan-Jie Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yan-Ni Ma *Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Xu-Hui Ma *Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. 118031@sh9hospital.org.cn.
Mei-Ling Hao *Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Rui-Xin Liu *Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yang Zheng *Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Jie YangShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Xiang-Yu ChenDepartment of Plastic and Cosmetic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Yi-Nan ChenShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Sheng-Nan ZhengShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yan-Jie ZhangShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Ming LeiShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Min JiangDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. jiangmin1023@suda.edu.cn.
Wei GuoDepartment of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. guoweicn@sjtu.edu.cn.
Han-Lin ZengShanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Hanlin.Zeng@shsmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While combination BRAF/MEK inhibition has improved survival in BRAF

Indexed as

Antineoplastic AgentsCell PlasticityMelanomaMicrophthalmia-Associated Transcription FactorPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafQuinolinesAnimalsCell Line, TumorCell ProliferationDrug SynergismHumansMice, NudeTyrosine Kinase InhibitorsAntineoplastic AgentsBRAF protein, humanMicrophthalmia-Associated Transcription FactorMITF protein, humanPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafQuinolinestivozanibTyrosine Kinase InhibitorsBRAF WT melanomacell state plasticityMITFtivozanibTT-012VEGFR2

Identifiers

PMID40550963
PMCPMC12644801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.